<DOC>
	<DOCNO>NCT02609828</DOCNO>
	<brief_summary>The purpose study determine whether tanezumab effective treatment cancer pain due bone metastasis patient already take background opioid therapy .</brief_summary>
	<brief_title>Phase 3 Study Efficacy Safety Tanezumab Patients With Cancer Pain Due Bone Metastasis Who Are Taking Background Opioid Therapy .</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , multicenter , parallel-group Phase 3 study cancer subject require treatment background opioids pain due bone metastasis . Approximately 170 subject randomize one 2 treatment group 1:1 ratio ( approximately 85 subject per group ) . Subjects receive total 3 subcutaneous injection , separate 8 week addition background opioids administer throughout study . Treatment group include : 1 . Placebo SC ( match tanezumab SC ) addition background opioid therapy . 2 . Tanezumab 20 mg SC addition background opioid therapy . The study consist three period : Pre-Treatment ( 37 day ) , Double-Blind Treatment ( 24 week ) Safety Follow-up ( 24 week ) .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Musculoskeletal Pain</mesh_term>
	<criteria>Personally sign date informed consent document . Willing able comply schedule visit , treatment plan , laboratory test , study procedure . Male female , ≥18 year age Weight ≥40 kg Screening Cancer diagnose metastasize bone multiple myeloma . Imaging confirmation bone metastasis Screening within 120 day prior Screening visit . Expected require daily opioid medication throughout course study . Willing use prohibit medication ( include NSAIDs ) throughout duration study . Average Pain Score ≥5 Screening index bone metastasis cancer pain site . Patient 's Global Assessment Cancer Pain `` fair '' , `` poor '' `` poor '' Screening . Eastern Cooperative Oncology Group ( ECOG ) Performance Status Score 0 , 1 , 2 Screening . Adequate bone marrow , renal liver function Screening . International Normalized Ratio ( INR ) prothrombin time ( PT ) &lt; 1.5 x ULN Screening unless treat anticoagulant medication . Females must either childbearing potential , childbearing potential risk pregnancy , must willing use least one highly effective method contraception throughout study 112 day ( 16 week ) last dose assign subcutaneous study medication . Pain related oncologic emergency . Brain metastasis leptomeningeal metastasis . Presence hypercalcemia Screening . Pain primarily classify predominantly relate bone metastasis . Systemic treatment primary malignancy bone metastasis start within 30 day Baseline Assessment Period . In Japan , chemotherapy associate peripheral neuropathy ( ie , paclitaxel , docetaxel , oxaliplatin , cisplatin , vincristine , thalidomide bortezomib ) prohibit study period 30 day prior first day Baseline Assessment Period Week 32 . Receipt radiopharmaceutical treatment radiotherapy treatment bone metastasis within 30 day Baseline Assessment Period . Concurrent adjuvant analgesic unless start least 30 day prior start Baseline Assessment Period maintain stable dose . Diagnosis osteoarthritis knee hip finding consistent osteoarthritis shoulder . History significant trauma surgery major joint within one year prior Screening . History osteonecrosis osteoporotic fracture . Xray evidence Screening : 1 ) rapidly progressive osteoarthritis , 2 ) atrophic hypotrophic osteoarthritis , 3 ) subchondral insufficiency fracture , 4 ) spontaneous osteonecrosis knee ( SPONK ) , 5 ) osteonecrosis , 6 ) pathologic fracture . Signs symptom clinically significant cardiac disease . Evidence orthostatic hypotension Screening Baseline prior randomization . Diagnosis transient ischemic attack 6 month prior Screening diagnosis stroke significant residual deficit . History , diagnosis , sign symptom clinically significant neurological disease . Total impact score &gt; 7 Survey Autonomic Symptoms ( SAS ) Screening . Past history carpal tunnel syndrome ( CTS ) sign symptom CTS one year prior Screening . History significant alcohol , analgesic , narcotic substance abuse within six month prior Screening . Planned surgical procedure duration study . Considered unfit surgery willing undergo joint replacement surgery require . Known hypersensitivity opioids underlie medical condition contraindicate opioid use . History allergic anaphylactic reaction therapeutic diagnostic monoclonal antibody IgGfusion protein . Previous exposure exogenous nerve growth factor antinerve growth factor antibody . Presence drug abuse , prescription medication without valid prescription illegal drug Screening . Positive Hepatitis B , Hepatitis C , Human Immunodeficiency Virus ( HIV ) test Screening indicative current infection . Investigational site staff member family member , Pfizer employee directly involve conduct trial . Participation study involve investigational drug ( ) within 30 day ( 90 day investigational biologics ) Baseline Assessment Period and/or study participation . Pregnant female subject ; breastfeed female subject ; female subject childbearing potential unwilling unable use one ( 1 ) highly effective method contraception throughout study 112 day last dose investigational product . Other severe acute chronic medical psychiatric condition laboratory abnormality .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Metastatic cancer bone pain</keyword>
	<keyword>Multiple myeloma</keyword>
</DOC>